Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03124459
Other study ID # A083-03
Secondary ID ACE-083
Status Terminated
Phase Phase 2
First received
Last updated
Start date July 31, 2017
Est. completion date March 11, 2020

Study information

Verified date September 2022
Source Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with Charcot-Marie-Tooth Disease Type 1 and Type X (CMT1 and CMTX), to be conducted in two parts. Part 1 is non-randomized, open-label, dose-escalation and Part 2 is randomized, double-blind, and placebo-controlled.


Description:

Part 1 (non-randomized, open-label, dose-escalation) Part 1 will consist of up to 3 cohorts of 6 patients each and will evaluate multiple ascending dose levels of ACE-083 administered bilaterally once every 3 weeks for up to 5 doses in the tibialis anterior (TA) muscle. Patients in each cohort will be enrolled in a 4-week screening period before beginning treatment. Part 2 (randomized, double-blind, placebo-controlled) Prior to the initiation of Part 2, a review of safety and efficacy data from Part 1 will be conducted by the Safety Review Team (SRT) to determine the recommended dose level (maximum 250 mg/muscle). A total of up to 40 new patients may be enrolled and randomized (1:1 randomization) to receive either ACE 083 (n=20) or placebo (n=20) bilaterally by injection into both TA muscles once every 3 weeks for up to 17 doses. Study duration for Parts 1 and 2 for each patient will be approximately 24 weeks, including a 4-week screening period, a 12-week treatment period, and an 8-week follow-up period after the last dose. Study duration for Part 2 will be 15 months, including 4-week screening, 6 months double blind placebo-controlled, 6 months open-label and 8 week follow-up.


Recruitment information / eligibility

Status Terminated
Enrollment 63
Est. completion date March 11, 2020
Est. primary completion date March 11, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria 1. Age = 18 years 2. Diagnosis of CMT1 or CMTX confirmed by: 1. Clinical presentation and electrodiagnostics 2. Genetically-confirmed CMT1 or CMTX for the patient or first-degree relative 3. Part 1: 1. Six-minute walk distance (6MWD) of at least 150 meters (without a brace or walker) 2. Independent ambulation for at least 10 meters, without a brace 3. Left and right ankle plantar flexion MRC grade 4+ to 5, inclusive Part 2: 1. 6MWD = 150 and = 500 meters (without a brace or walker); a maximum of 20% of enrolled patients with 6MWD = 450 meters will be included 2. Left and right ankle plantar flexion MRC grade 4- to 5, inclusive 4. Left and right ankle dorsiflexion Medical Research Council (MRC) manual muscle testing (MMT) grade 3 to 4+ inclusive. No more than 12 of the 40 subjects may have a grade of 3 or 3+ on one or both sides. 5. Females of childbearing potential must have negative urine pregnancy test prior to enrollment and use highly effective birth control methods during study participation and for 8 weeks following the last dose of ACE-083. Males must agree to use a condom during any sexual contact with females of childbearing potential while participating in the study and for 8 weeks following the last dose of ACE-083, even if he has undergone a successful vasectomy. 6. Ability to adhere to the study visit schedule/procedures, and to understand and comply with protocol requirements 7. Signed written informed consent Key Exclusion Criteria 1. History of active malignancy, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or = 2 squamous cell carcinomas of the skin 2. Symptomatic cardiopulmonary disease, significant functional impairment, significant orthopedic or neuropathic pain, or other co morbidities that in the opinion of the investigator would limit a patient's ability to complete strength and/or functional assessments on study 3. Type 1 or type 2 diabetes mellitus 4. Thyroid disorder unless condition is stable with no change in treatment for at least 4 weeks before the first dose and no expected change for duration of study 5. Renal impairment (serum creatinine = 2 times the upper limit of normal (ULN]) 6. Aspartate transaminase (AST) and/or alanine transaminase (ALT) = 3 times ULN 7. Increased risk of bleeding (i.e., due to hemophilia, platelet disorders, or use of any anticoagulation/platelet modifying therapies up to 2 weeks prior to Study Day 1 and for duration of study; low dose aspirin [= 100 mg daily] is permitted) 8. Severe deformity or ankle fixation that would sufficiently limit passive range of motion to affect assessment of dorsiflexion strength 9. Major surgery within 4 weeks prior to Study Day 1 10. Chronic pharmacologic doses of systemic corticosteroids (= 2 weeks) within 4 weeks before Study Day 1 and for duration of study; intra-articular/topical/inhaled/intranasal physiologic doses of systemic corticosteroids are permitted 11. Androgens, growth hormone, insulin or oral hormone replacement therapy within 6 months before Study Day 1 and for duration of study; topical physiologic androgen replacement is permitted 12. Any change in medications potentially affecting muscle strength or function within 4 weeks of Study Day 1 and for duration of study (e.g., creatinine, CoQ10, systemic beta-adrenergic agonists) 13. Previous exposure to any investigational agent potentially affecting muscle volume, muscle strength, or muscle or nerve function within 5 half-lives of last dose plus an additional 8-week washout period (or 12 weeks prior to Study Day 1 if half-life is unknown) 14. Any previous or current exposure to ACE-083 15. Significant change in physical activity or exercise (e.g., significant increase or decrease in intensity or frequency) within 8 weeks before Study Day 1 or inability to maintain the baseline level of physical activity throughout the study 16. Any condition that would prevent MRI scanning or compromise the ability to obtain a clear and interpretable scan of the lower leg, as applicable (e.g., knee/hip replacement metallic implants) 17. Known active substance abuse, including alcohol 18. History of sensitivity to protein pharmaceuticals 19. Female that is lactating/breast-feeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ACE-083
Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
Placebo
Recombinant fusion protein or buffer solution

Locations

Country Name City State
United States University of Colorado Aurora Colorado
United States University of Vermont Burlington Vermont
United States Carolinas Healthcare System Neurosciences Institute Charlotte North Carolina
United States University of Florida Gainesville Florida
United States Hackensack University Medical Center Hackensack New Jersey
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States University of Kansas Medical Center - Neurology Department Kansas City Kansas
United States University of Minnesota, Neurology Department Minneapolis Minnesota
United States Columbia University New York New York
United States University of California-Irvine Orange California
United States University of Pennsylvania Philadelphia Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States Virginia Commonwealth University Richmond Virginia
United States University of Rochester Medical Center, Neurology Rochester New York
United States Washington University School of Medicine Saint Louis Missouri
United States University of Utah Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Frequency of Adverse Events Number of subjects with at least one adverse event related to treatment intervention from Part 1 of this study. Since this outcome measure was only pre-specified for Part 1, only data from the Part 1 participants is reported. From initiation of treatment (Study Day 1) to end of follow-up period for Part 1 (Study Day 141).
Primary Part 2: Percent Change in Muscle Volume to the End of the Double-blind Placebo-controlled Portion of the Study. The percent change from baseline in volume of injected muscle, by MRI compared to the Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).
Secondary Part 2: Absolute Change in Amount of Intramuscular Fat Tissue to the End of the Double-blind Placebo-controlled Portion of the Study The absolute change from baseline in intramuscular fat fraction of the injected muscle, by MRI compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).
Secondary Part 2: Percent Change in Muscle Strength to the End of the Double-blind Placebo-controlled Portion of the Study Percent change from baseline in strength of the injected muscle, by Quantitative Muscle Testing (QMT) compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).
Secondary Part 2: Percent Change in Muscle Function - Walk/Run Time to the End of the Double-blind Placebo-controlled Portion of the Study The percent change from baseline in functional assessments, as measured by 10-meter walk/run time when compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).
Secondary Part 2: Percent Change in Muscle Function - Walk Distance Assessed at the End of the Double-blind Placebo-controlled Portion of the Study Percent change from baseline in functional assessments, as measured by 6-minute walk distance when compared to Day 190 Assessment, is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period for the double-blind placebo-controlled portion of the study (Study Day 190).
Secondary Part 2: Change in Balance and Fall Risk at the End of the Double-blind Placebo-controlled Portion of the Study. Change from baseline in static and dynamic balance, as measured by the Berg Balance Scale, a 14-item scoring system to assess balance and fall risk in adults. The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function. Total scores are used for reporting, with a range of 0-56, with higher scores mean a better demonstration of function. A score of 56 indicates functional balance. A score of < 45 indicates individuals may be at greater risk of falling. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).
Secondary Part 2: Percent Change in Balance and Fall Risk From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study Percent change was calculated for the difference from baseline and Day 190 Assessment scores on the Berg Balance Scale. The Berg Balance Scale, is a 14-item scoring system to assess balance and fall risk in adults. The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function. Total scores are used for reporting, with a range of 0-56, with higher scores mean a better demonstration of function. A score of 56 indicates functional balance. A score of < 45 indicates individuals may be at greater risk of falling. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).
Secondary Part 2: Change in Clinical Examination Score From Baseline to End of the Double-blind Placebo-controlled Portion of the Study Change from baseline in the Charcot-Marie-Tooth (CMT) Examination Score, version 2 (CMTES2), a composite scoring system to assess sensory and motor impairment in subjects with CMT. The total score is a subset of the following items from the CMT neuropathy score instrument: Sensory symptoms, Motor symptoms (legs), Motor symptoms (arms), Pinprick Sensibility, Vibration, Strength (legs), and Strength (arms). Each individual item is assessed using a rating from 0 to 4 inclusive. The range of CMTES2 scores is from 0 to 28 inclusive. A higher score means a greater degree of symptom severity. The Baseline score and score on the Day 190 Assessment are reported. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).
Secondary Part 2: Percent Change in Clinical Examination Score in Baseline to End of the Double-blind Placebo-controlled Portion of the Study Percent change was calculated for the difference in the Charcot-Marie-Tooth (CMT) Examination Score (CMTES2) from baseline and Day 190 Assessment scores. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).
Secondary Part 2: Change in Patient-reported Quality of Life From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study The absolute change from baseline in Charcot-Marie-Tooth Health Index (CMT-HI), a disease-specific, patient-reported health index score from baseline and Day 190 Assessment scores. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported. From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).
See also
  Status Clinical Trial Phase
Recruiting NCT06203093 - Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for iPSC Generation and Biobanking
Recruiting NCT03782883 - The Impact of Charcot-Marie-Tooth Disease in the Real World
Recruiting NCT02979145 - Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611) N/A
Terminated NCT03254199 - A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps. Phase 2
Completed NCT02011204 - Study of Electrical Impedance Myography (EIM) in ALS N/A
Completed NCT00149045 - Follow up and Observation of Charcot Marie Tooth Disease in Families N/A
Completed NCT04786522 - Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease
Recruiting NCT05011006 - NT-3 Levels and Function in Individuals With CMT
Recruiting NCT05902351 - Natural History Study for Charcot Marie Tooth Disease
Terminated NCT03943290 - Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) Phase 2
Active, not recruiting NCT04762758 - Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients Phase 3
Completed NCT02788734 - Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies N/A
Recruiting NCT02532244 - Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
Terminated NCT05827419 - Hearing and Balance Disorders in Peripheral Neuropathy
Terminated NCT03810508 - A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)
Recruiting NCT04010188 - A Registered Cohort Study on Charcot-Marie-Tooth Disease
Completed NCT00271635 - Ascorbic Acid Treatment in CMT1A Trial (AATIC) Phase 2
Completed NCT03715283 - Change in MUNIX in Patients With CMT1A Undergoing a Home Ankle Strengthening Program Versus Standard of Care N/A
Completed NCT02001038 - Survey of Current Management of Orthopaedic Complications in CMT Patients N/A
Not yet recruiting NCT01289704 - Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) Phase 2/Phase 3